Miao Hu

B. Tomlinson, Miao Hu, Yajie Xiao, 2014, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

Translational Research for Improving the Care of Familial Hypercholesterolemia: The "Ten Countries Study" and Beyond.

S. Yamashita, G. Watts, M. Hagger, 2016, Journal of atherosclerosis and thrombosis.

Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients.

B. Tomlinson, Hon-Kit Lee, C. Ho, 2013, Pharmacogenomics.

Ezetimibe treatment should be considered for patients with sitosterolemia

B. Tomlinson, Miao Hu, 2014, Pediatric Nephrology.

Liraglutide for weight management: benefits and risks

B. Tomlinson, Yuzhen Zhang, Miao Hu, 2017, Current medical research and opinion.

Telmisartan increases systemic exposure to rosuvastatin after single and multiple doses, and in vitro studies show telmisartan inhibits ABCG2-mediated transport of rosuvastatin

J. Chan, Z. Zuo, K. To, 2016, European Journal of Clinical Pharmacology.

Response to the letter "No evidence to support high-intensity statin in Chinese patients with coronary heart disease".

B. Tomlinson, Yuzhen Zhang, Miao Hu, 2016, International journal of cardiology.

Do the lipid responses to rosuvastatin and atorvastatin differ between Chinese and Caucasians? Comparison of the DISCOVERY-Hong Kong study with other DISCOVERY studies.

B. Tomlinson, G. Ko, Miao Hu, 2013, International journal of cardiology.

Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes

B. Tomlinson, Yuzhen Zhang, Miao Hu, 2016, Expert opinion on drug metabolism & toxicology.

The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins

K. To, B. Tomlinson, Miao Hu, 2011, Expert opinion on drug metabolism & toxicology.

Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients

B. Tomlinson, L. Baum, V. Lee, 2010, Pharmacogenetics and genomics.

Effect of common polymorphisms of the farnesoid X receptor and bile acid transporters on the pharmacokinetics of ursodeoxycholic acid

Z. Zuo, B. Tomlinson, Miao Hu, 2016, Clinical and experimental pharmacology & physiology.

Effects of grapefruit juice and SLCO1B1 388A>G polymorphism on the pharmacokinetics of pitavastatin.

B. Tomlinson, O. Yin, Miao Hu, 2013, Drug metabolism and pharmacokinetics.

Effects of Soy Isoflavones and Green Tea Extract on Simvastatin Pharmacokinetics and Influence of the SLCO1B1 521T > C Polymorphism

B. Tomlinson, C. Lau, Hon-Kit Lee, 2022, Frontiers in Nutrition.

Heterozygous familial hypercholesterolemia in Hong Kong Chinese. Study of 252 cases.

B. Tomlinson, C. Pang, Miao Hu, 2013, International journal of cardiology.

Fully automatic and nonparametric quantification of adipose tissue in fat–water separation MR imaging

Brian Tomlinson, Defeng Wang, Lin Shi, 2015, Medical & Biological Engineering & Computing.

Theranostics meets traditional Chinese medicine: rational prediction of drug–herb interactions

B. Tomlinson, Honghao Zhou, Miao Hu, 2012, Expert review of molecular diagnostics.

Safety of statins: an update

B. Tomlinson, B. Cheung, Miao Hu, 2012, Therapeutic advances in drug safety.

Febuxostat in the management of hyperuricemia and chronic gout: a review

B. Tomlinson, Miao Hu, 2008, Therapeutics and clinical risk management.

Potential effects of NPC1L1 polymorphisms in protecting against clinical disease in a chinese family with sitosterolaemia.

J. Griffith, B. Tomlinson, Y. Yuen, 2014, Journal of atherosclerosis and thrombosis.

Molecular characterization of a Chinese woman homozygous for the familial hypercholesterolemia LDLR c.1474G>A (p.Asp492Asn) mutation

B. Tomlinson, Miao Hu, A. Hooper, 2014 .

Predicting intention to participate in self-management behaviors in patients with Familial Hypercholesterolemia: A cross-national study.

G. Watts, M. Hagger, R. Santos, 2019, Social science & medicine.

Evolocumab for the treatment of hypercholesterolemia

B. Tomlinson, Yuzhen Zhang, Miao Hu, 2017, Expert opinion on biological therapy.

Alirocumab for the treatment of hypercholesterolemia

B. Tomlinson, Yuzhen Zhang, Miao Hu, 2017, Expert opinion on biological therapy.

Achilles Tendon Xanthomas: Fat-Water Separation at Baseline and after Treatment.

Defeng Wang, D. Yeung, J. Griffith, 2017, Radiology.

The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure

B. Tomlinson, S. Chan, Miao Hu, 2012, Expert opinion on drug metabolism & toxicology.

Development of genome-wide polygenic risk scores for lipid traits and clinical applications for dyslipidemia, subclinical atherosclerosis, and diabetes cardiovascular complications among East Asians

R. Ozaki, A. Kong, J. Chan, 2021, Genome medicine.

Lipid disorders in Chinese populations

B. Tomlinson, G. Thomas, Miao Hu, 2011 .

Pharmacogenomics of lipid-lowering therapies.

B. Tomlinson, Miao Hu, 2013, Pharmacogenomics.

Fully automatic and nonparametric quantification of adipose tissue in fat–water separation MR imaging

P. Heng, Lin Shi, W. Chu, 2015, Medical & Biological Engineering & Computing.

Lipid-lowing pharmacogenomics in Chinese patients

B. Tomlinson, Miao Hu, 2013, Expert review of cardiovascular therapy.

Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia.

B. Tomlinson, Miao Hu, Yajie Xiao, 2013, Pharmacogenomics.

Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease

M. Waye, B. Tomlinson, Miao Hu, 2009 .

In vivo assessment of herb-drug interactions: possible utility of a pharmacogenetic approach?

B. Tomlinson, V. Lee, Miao Hu, 2008, Molecular nutrition & food research.

Effects of Some Common Food Constituents on Cardiovascular Disease

B. Tomlinson, S. Chan, Miao Hu, 2011, ISRN cardiology.

Effects of Phenotypic and Genotypic Factors on the Lipid Responses to Niacin in Chinese Patients With Dyslipidemia

S. Yamashita, B. Tomlinson, V. Lee, 2015, Medicine.

Current Perspectives on rosuvastatin

B. Tomlinson, Miao Hu, 2013, Integrated blood pressure control.

Pharmacogenetics of cutaneous flushing response to niacin/laropiprant combination in Hong Kong Chinese patients with dyslipidemia.

Brian Tomlinson, B. Tomlinson, Miao Hu, 2015, Pharmacogenomics.

Patients with sitosterolaemia , in whom there is Potential Effects of NPC 1 L 1 Polymorphisms in Protecting against Clinical Disease in a Chinese Family with Sitosterolaemia

J. Griffith, B. Tomlinson, Y. Yuen, 2014 .

Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia.

G. Watts, M. Hagger, R. Santos, 2018, Atherosclerosis.

RUNNING HEAD: Treatment Beliefs and Intention to Take Medication in FH 1 FH Special issue-Effects of Medication, Treatment, and Behavioral Beliefs on Intentions to Take Medication in Patients with Familial Hypercholesterolemia

M. Hagger, R. Santos, S. Hardcastle, 2018 .

Associations of polymorphisms in the apolipoprotein A1/C3/A4/A5 gene cluster with familial combined hyperlipidaemia in Hong Kong Chinese.

Brian Tomlinson, B. Tomlinson, L. Baum, 2010, Atherosclerosis.

Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patients

W. Chu, S. Yamashita, Defeng Wang, 2012, Journal of Lipid Research.

Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes

B. Tomlinson, Yuzhen Zhang, Miao Hu, 2017, Expert opinion on drug metabolism & toxicology.

Early investigational drugs targeting PPAR-α for the treatment of metabolic disease

B. Tomlinson, Miao Hu, Zhong-min Liu, 2015, Expert opinion on investigational drugs.

Effects of Concomitant Therapy with Diltiazem on the Lipid Responses to Simvastatin in Chinese Subjects

B. Tomlinson, Miao Hu, J. You, 2010, Journal of clinical pharmacology.

Achievement of specified lipid and high-sensitivity C-reactive protein levels with two statins in Chinese patients with hypercholesterolaemia

B. Tomlinson, Yong-Jian Wu, Miao Hu, 2015, Lipids in Health and Disease.

Effect of Green Tea Extract and Soy Isoflavones on the Pharmacokinetics of Rosuvastatin in Healthy Volunteers

B. Tomlinson, C. Lau, Hon-Kit Lee, 2022, Frontiers in Nutrition.

Current status of personalized medicine based on pharmacogenetics in cardiovascular medicine

M. Waye, B. Tomlinson, Miao Hu, 2016 .

Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin

B. Tomlinson, Miao Hu, 2014, Expert opinion on drug metabolism & toxicology.

The farnesoid X receptor -1G>T polymorphism influences the lipid response to rosuvastatin[S]

B. Tomlinson, L. Tam, E. Li, 2012, Journal of Lipid Research.

Evaluation of a Crataegus-Based Multiherb Formula for Dyslipidemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

B. Tomlinson, Miao Hu, Weiwei Zeng, 2014, Evidence-based complementary and alternative medicine : eCAM.

Effects of CYP2D6*10, CYP3A5*3, CYP1A2*1F, and ABCB1 C3435T polymorphisms on the pharmacokinetics of flecainide in healthy Chinese subjects

B. Tomlinson, S. Chan, O. Yin, 2012, Drug metabolism and drug interactions.

Factors Associated with Aspirin Resistance in Hong Kong Chinese Patients with Stable Coronary Heart Disease Using the Multiplate® Analyzer and Serum Thromboxane B2

B. Yan, B. Tomlinson, Elaine Chow, 2022, Pharmaceutics.

Achievement of specified lipid and high-sensitivity C-reactive protein levels with two statins in Chinese patients with hypercholesterolaemia

B. Tomlinson, Yong-Jian Wu, Miao Hu, 2015, Lipids in Health and Disease.

CYP2C19 genotype has a major influence on labetalol pharmacokinetics in healthy male Chinese subjects

B. Tomlinson, S. Chan, M. Chow, 2013, European Journal of Clinical Pharmacology.

Simultaneous Determination of Cortisol, Cortisone, and 6β-Hydroxycortisol in Human Urine by UPLC with UV Detector and Application to Determine Diurnal Variations

B. Tomlinson, S. Chan, E. Poon, 2012, Chromatographia.

Impact of CYP2D6 polymorphisms on the pharmacokinetics of lovastatin in Chinese subjects

B. Tomlinson, M. Chow, O. Yin, 2012, European Journal of Clinical Pharmacology.

S. Yamashita, G. Watts, A. Ramli, 2017, BMJ Open.

Effect of central obesity, low high-density lipoprotein cholesterol and C-reactive protein polymorphisms on C-reactive protein levels during treatment with Rosuvastatin (10 mg Daily).

B. Tomlinson, Miao Hu, V. Mak, 2010, The American journal of cardiology.

Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin

B. Tomlinson, Miao Hu, 2014, Expert opinion on drug metabolism & toxicology.

Polymorphisms in apolipoprotein E and apolipoprotein A-V do not influence the lipid response to rosuvastatin but are associated with baseline lipid levels in Chinese patients with hyperlipidemia.

B. Tomlinson, Miao Hu, V. Mak, 2012, Journal of clinical lipidology.

Effects of statin treatments and polymorphisms in UGT1A1 and SLCO1B1 on serum bilirubin levels in Chinese patients with hypercholesterolaemia.

B. Tomlinson, Miao Hu, 2012, Atherosclerosis.

Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients

B. Tomlinson, L. Baum, L. Tam, 2010, Pharmacogenetics and genomics.

Pharmacogenomics of lipid-lowering therapies.

B. Tomlinson, Miao Hu, 2013, Pharmacogenomics.

ABCG2 Polymorphism Is Associated With the Low‐Density Lipoprotein Cholesterol Response to Rosuvastatin

B. Tomlinson, L. Baum, V. Lee, 2010, Clinical pharmacology and therapeutics.

CYP2C19 genotype has a major influence on labetalol pharmacokinetics in healthy male Chinese subjects

B. Tomlinson, S. Chan, Miao Hu, 2012, European Journal of Clinical Pharmacology.